MedTrace Logo

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04917770 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-06-08

No results posted yet for this study

Summary

Nasopharyngeal carcinoma is the most common malignant tumor of head and neck in southern China. After standard treatment, about 20% of the patients had local recurrence or distant metastasis, and the patients faced death in a short time. Currently, there is no recommended treatment for patients with recurrent or metastatic nasopharyngeal carcinoma who have unsatisfactory results of first-line chemotherapy and subsequent immunotherapy. Patients who have failed multiline therapy have a low survival rate and no drugs are available.This project aims to evaluate the efficacy and safety of sintilimab in combination with multimodal radiotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma who have previously received immunotherapy and still progress after multiline therapy, and to seek a new therapeutic approach for such patients.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Sintilimab in combination with Multimodality Radiotherapy

Participants will be treated with sintilimab in combination with multimodality radiotherapy

Sponsors & Collaborators

  • Chengdu City No.2 People's Hospital

    collaborator UNKNOWN

  • No.3 People's Hospital of Chengdu

    collaborator UNKNOWN

  • Sichuan Provincial People's Hospital

    collaborator OTHER

  • The First People's Hospital of Ziyang

    collaborator UNKNOWN

  • No.5 People's Hospital of Chengdu

    collaborator UNKNOWN

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-06-30
Completion
2024-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04917770 on ClinicalTrials.gov